Vigil drug fails a Phase 2; Merus aims to raise $300M
Plus, news about Bayer: Vigil Neuroscience's Phase 2 fail: The neurodegenerative disease biotech stopped a long-term extension trial of iluzanebart for a rare disease called adult-onset leukoencephalopathy with axonal spheroids and ...
Plus, news about Bayer:
Vigil Neuroscience's Phase 2 fail: The neurodegenerative disease biotech stopped a long-term extension trial of iluzanebart for a rare disease called adult-onset leukoencephalopathy with axonal spheroids and ...
